RG-7351

RG-7351 is a trace amine-associated receptor 1 (TAAR1) partial agonist that is or was under development for the treatment of major depressive disorder.

Uses your system voice; voice and rate in settings.

Snapshot

≈ 1 min read

Names in other languages

No names in other languages are held for this entry yet.

Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.

RG-7351 is a trace amine-associated receptor 1 (TAAR1) partial agonist that is or was under development for the treatment of major depressive disorder. It reached phase 1 clinical trials for this indication in 2010. However, as of November 2023, no further recent development has been reported since July 2016. The drug was developed by Hoffmann-La Roche.

Text derived from https://en.wikipedia.org/w/index.php?oldid=1372045792 under CC BY-SA 4.0; modifications have been made.

Sources cited in this revision

2 named source(s) extracted from the cited revision. A source with no author is shown by its publication; nothing is invented.